Hypothesis

Systemic elevation of NAD+ via NMN alone fails to fully activate SIRT6 at heterochromatic transposable element (TE) loci because PARP1 competes for the same NAD+ pool and its chronic activation in aging depletes local NAD+ concentrations. When PARP1 activity is pharmacologically inhibited, more NAD+ becomes available for SIRT6, allowing its recruitment to HP1α‑containing chromatin and robust deacetylation of H3K9ac at LINE‑1 and IAP promoters. This synergistic intervention should restore heterochromatin marks (H3K9me3) and suppress TE transcription beyond what either NMN or PARP1 inhibition achieves alone.

Mechanistic Rationale

• SIRT6 requires NAD+ as a co‑factor for its deacetylase activity and is recruited to heterochromatin through interaction with HP1α, a process favoured when H4K20me3 is present.
• In aged tissues, PARP1 is persistently activated by accumulating DNA strand breaks, consuming large amounts of NAD+ and creating a subcellular NAD+ deficit that limits SIRT6 despite systemic supplementation.
• Inhibiting PARP1 spares NAD+, shifts the NAD+/NADH ratio toward a state that favours sirtuin activity, and reduces PAR‑dependent chromatin relaxation, thereby stabilizing heterochromatin boundaries.

Thus, the hypothesis integrates NAD+ metabolism, DNA‑damage signalling, and chromatin‑based SIRT6 recruitment into a single testable model.

Experimental Plan

Model: C57BL/6 mice aged 20‑24 months, representing natural aging with elevated TE expression and PARP1 activity.

Groups (n=8 per group):

1. Vehicle control
2. NMN supplementation (300 mg/kg/day, oral)
3. PARP1 inhibitor (Olaparib 10 mg/kg/day, intraperitoneal)
4. Combined NMN + PARP1 inhibitor

Readouts (after 4 weeks):

• NAD+ levels in liver and hippocampus by LC‑MS/MS to confirm systemic boost.
• Chromatin immunoprecipitation‑seq for SIRT6, H3K9ac, H3K9me3, and HP1α at LINE‑1 and IAP promoters.
• TE expression quantified by RT‑qPCR and RNA‑seq (transposon‑aware mapping).
• DNA damage markers (γH2AX foci) to verify PARP1 inhibition does not exacerbate lesions.
• Senescence biomarkers (p16^INK4a^, SA‑β‑gal) to assess functional impact.

Predicted Outcomes

• NMN alone raises total NAD+ but does not significantly change SIRT6 occupancy or H3K9me3 at TE loci compared with vehicle.
• PARP1 inhibitor alone modestly increases SIRT6 binding due to reduced PAR competition but limited by lower NAD+ availability.
• The combination yields a synergistic increase in SIRT6 chromatin occupancy, heightened H3K9me3 deposition, decreased H3K9ac at TE promoters, and a >50 % reduction in LINE‑1/IAP transcripts relative to either monotherapy.
• Improved heterochromatin integrity correlates with reduced senescence markers and lower γH2AX foci, supporting a functional link between SIRT6‑mediated TE suppression and genomic stability.

Falsifiability

If the combined treatment fails to produce a statistically significant increase in SIRT6 binding or H3K9me3 at TE loci, or if TE expression remains unchanged relative to NMN alone, the hypothesis is refuted. Conversely, a clear synergistic effect as described would support the model that NAD+ availability must be coupled with PARP1 modulation to unleash SIRT6’s heterochromatin‑protective function during aging.